Literature DB >> 1956607

Stressor-induced anhedonia in the mesocorticolimbic system.

R M Zacharko1, H Anisman.   

Abstract

It has been suggested that uncontrollable stressors induce motivational changes in animals which are reminiscent of reward alteration in human depression. Although there is considerable support for this position, most animal models of depression do not adequately address this issue. The present review suggests that stressor-induced reductions in the rewarding value of electrical brain stimulation (ICSS) from the mesocorticolimbic system may simulate the anhedonia of human depression. The magnitude, severity and the site of these stressor-induced reward alterations within the mesocorticolimbic system vary with the strain of animal employed. The anhedonic effects of stressors are attenuated by treatments which influence mesocorticolimbic DA turnover, including systemic antidepressant and intraventricular neuropeptide administration. Although the diverse symptom profile of depression should be addressed by consideration of the constellation of behavioral disturbances induced by stressors, considerable emphasis should be devoted to an assessment of reward loss in depression. The implications of these data to the stressor depression topography and the potential role of mesocorticolimbic DA in depression and anhedonia are discussed.

Entities:  

Mesh:

Year:  1991        PMID: 1956607     DOI: 10.1016/s0149-7634(05)80032-6

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  33 in total

1.  Prophylactic actions of the antioxidant agent AEKOL on behavioral (psychoemotional) disturbances induced by chronic stress in rats.

Authors:  M A Kulikov
Journal:  Neurosci Behav Physiol       Date:  2001 Sep-Oct

2.  Effect of stress on opioid-seeking behavior: evidence from studies with rats.

Authors:  Y Shaham
Journal:  Ann Behav Med       Date:  1996

3.  CRF mediates the anxiogenic and anti-rewarding, but not the anorectic effects of PACAP.

Authors:  Riccardo Dore; Attilio Iemolo; Karen L Smith; Xiaofan Wang; Pietro Cottone; Valentina Sabino
Journal:  Neuropsychopharmacology       Date:  2013-05-09       Impact factor: 7.853

4.  Basal microRNA expression patterns in reward circuitry of selectively bred high-responder and low-responder rats vary by brain region and genotype.

Authors:  David E Hamilton; Christopher L Cooke; Bradley S Carter; Huda Akil; Stanley J Watson; Robert C Thompson
Journal:  Physiol Genomics       Date:  2014-02-25       Impact factor: 3.107

5.  Alterations in the levels of monoamines in discrete brain regions of clomipramine-induced animal model of endogenous depression.

Authors:  M Vijayakumar; B L Meti
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

6.  Exposure to mild stress enhances the reinforcing efficacy of intravenous heroin self-administration in rats.

Authors:  Y Shaham; J Stewart
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

7.  Withdrawal from chronic amphetamine elevates baseline intracranial self-stimulation thresholds.

Authors:  R A Wise; E Munn
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

8.  Role of dopamine D2 receptors in plasticity of stress-induced addictive behaviours.

Authors:  Hye-Ri Sim; Tae-Yong Choi; Hyo Jin Lee; Eun Young Kang; Sehyoun Yoon; Pyung-Lim Han; Se-Young Choi; Ja-Hyun Baik
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models.

Authors:  Matthew B Wilkinson; Guanghua Xiao; Arvind Kumar; Quincey LaPlant; William Renthal; Devanjan Sikder; Thomas J Kodadek; Eric J Nestler
Journal:  J Neurosci       Date:  2009-06-17       Impact factor: 6.167

Review 10.  Drug withdrawal conceptualized as a stressor.

Authors:  Elena H Chartoff; William A Carlezon
Journal:  Behav Pharmacol       Date:  2014-09       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.